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AbstrACt
Cholera is an acute bacterial gastrointestinal infection caused by ingestion of water or food containing the 
pathogen Vibrio cholerae. The incubation period can be very short and it takes between several hours and  
5 days. During the 19th century, cholera was spreading from India across the world. Its original reservoir was 
located in the Ganges delta. So far, there have been six epidemics of cholera; the current outbreak is the 
seventh. It started in Asia, attacked Africa and then the Americas. Cholera causes thousands of illnesses 
and deaths annually, mostly in South Asia and Sub-Saharan Africa. The current outbreak began in Yemen 
in October 2016, it peaked in December with subsequent decline, then the epidemic has re-erupted in 
April 2017 and it still continues. It is currently the largest outbreak in the world, with 5000 new infections 
a day (as of August 19th, 2017 the number of cholera cases stands at 527,000 with 1997 deaths). The 
most common symptoms of the illness are diarrhoea, dehydration, vomiting, and abdominal cramps. 
Case-fatality rate is lower than 1%, if rehydration treatment is prescribed rapidly, but it can exceed 70% 
in patients not treated properly. Aggressive and rapid fluid repletion is the basis of treatment for cholera. 
In many cases, rehydration therapy, given orally or parenterally, is enough to rescue infected patients. 
Antibiotics, mainly fluoroquinolones, tetracyclines, and macrolides are an adjunctive therapy for patients 
with moderate to severe fluid loss.  
(Int Marit Health 2017; 68, 3: 163–167)
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ETIOLOGICAL FACTOR
Cholera is a bacterial disease caused by an infection of 
small intestine by Vibrio cholerae after ingestion of products 
contaminated with toxigenic strains, serogroups O1 and 
O139 [1]. Vibrio cholerae is a distinctive, comma-shaped 
gram-negative rod. Besides O1 and O139 strains, there 
are many other serogroups of V. cholerae, but they do not 
cause outbreaks. Other serogroups are classified as Vibrio 
cholerae “non-O1, non-O139”. Toxin-producing non-O1/ 
/O139 strains are linked to isolated cases of dehydrating 
diarrhoea. Non-toxin-producing non-O1/O139 strains have 
been associated with sepsis and gastroenteritis [2]. 
The O139 strain was discovered in 1992 in Bangla-
desh and has never been identified outside Asia. It caused 
outbreaks in the recent decades. Nowadays, it is only spo-
radically found. V. cholerae O1 is the cause of the current 
epidemic of cholera. 
There is no difference in the course of the illness caused 
by the two serogroups; clinically they are indistinguishable 
[3]. Vibrio cholerae toxin is the virulence factor causing the 
cholera disease, which is characterised by an acute watery 
diarrhoea [4]. It is the cholera toxin which is the primary 
reason for the characteristic profuse watery diarrhoea. Only 
toxigenic strains (toxin-producing) of Vibrio cholerae are 
associated with cholera. After colonisation of the intestinal 
epithelium, the bacteria secretes cholera toxin [2]. 
sYMPtOMs
Cholera is an extremely virulent disease. The incuba-
tion period can be very short and it takes between several 
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hours and 5 days [5]. It lasts typically 1 to 2 days. Although 
most people infected with V. cholerae do not develop any 
symptoms, the pathogen can be detected in their stool 
samples for 1–10 days after infection and it is shed back 
into the environment. It is an important issue, because of 
the potential for infecting other people [3].
Symptomatic patients may present with a mild infection 
or severe watery diarrhoea that can be fatal in several hours 
(cholera gravis). After ingestion, the bacteria experience the 
acidic gastric environment and if they survive, they will form 
colonies adhering to the small intestine epithelium. Once 
attached to the surface of the small intestine, V. cholerae 
begin to produce cholera toxin that is responsible for the 
secretory watery diarrhoea [2]. 
Abdominal discomfort, malaise, cramps and vomiting 
are common accompanying early symptoms of the infection. 
Fever, severe abdominal pain, tenesmus are uncommon. 
Patients presenting with elevated temperature probably 
have coinfection or complications. 
The hallmark of cholera is the rapid passage of large 
amounts of “rice-water” stool, sometimes including mu-
cus. The diarrhoea is usually painless, it can have fishy 
odour or is odourless. Complications are associated with 
massive fluid and electrolytes (sodium, potassium, bi-
carbonate and chloride) depletion [6]. Such significant 
fluid loss is unusual for other diarrhoeal infections. It 
can be as high as 1 litre per hour in adult patients [7]. 
Bacteraemia is rare. 
Cholera sicca (dry cholera) is a rare form of the disease. 
Death can occur within hours as a result of circulatory col-
lapse. Because of the accumulation of fluid in the intestines, 
diarrhoea — the typical symptom of cholera — is absent [8]. 
If properly treated, cholera does not cause any known 
long-term complications or sequels. 
DIAGNOSIS
Most cases of cholera are found in resource-limited 
regions of the world and are diagnosed presumptively in 
patients with acute watery diarrhoea with rapid and severe 
volume depletion. The experience of medical staff is crucial, 
because only prompt and aggressive rehydration therapy 
can save the life of patients with cholera gravis. It is worth 
emphasizing that in many tropical settings, stool culture or 
even microscopy is not available. 
The preliminary diagnosis can be confirmed by rapid 
dipsticks tests, dark field microscopy, identifying V. cholerae 
in stool samples and isolation of bacteria from stool cultures 
[9]. Rapid dipsticks tests have low specificity which limits 
significantly their use in endemic areas. 
The most important abnormalities confirmed by labora-
tory examinations are electrolyte disturbances, e.g. hypo-
kalaemia, hyponatraemia, hypocalcaemia. Acidosis is also 
frequently seen. In cases with circulatory collapse and fluid 
loss, there is a risk of renal failure. 
TREATMENT
Cholera is an easily treatable disease. Eighty per cent of 
cases can be effectively treated with rehydration therapy. In 
many endemic areas, ready-made oral rehydration solutions 
are available. They must be prepared with clean, treated 
water. For more severe cases, an antibiotic course may be 
necessary. Adults will need 6 or more litres of oral rehydra-
tion solutions in the first 24 h of infection. In more severe 
cases, patients require intravenous rehydrating therapy. 
The total volume loss may be even equal with a patient’s 
body weight [10]. 
When patients are successfully treated, symptoms are 
most serious in the first 2 days, and then they are dimin-
ishing. Without prompt treatment, cholera can be fatal 
within hours. The degree of fluid loss should be catego-
rised according to World Health Organisation (WHO) criteria 
of none (< 5% of body weight), some (5–10%), or severe 
(> 10%) based on physical examination. 
Antibiotics are necessary in moderate or severe cholera 
and shorten the duration of diarrhoea, minimize V. cholerae 
shedding in stool and decrease the amount of rehydration 
fluids needed during the therapy [3]. The antibiotics used 
for cholera include fluoroquinolones, tetracyclines and mac-
rolides [11]. Antibiotics reduce the duration of excretion of 
V. cholerae in stool, diminish the possibility of infection 
among family members and minimise the risk of a nosoco-
mial infection [4]. Resistance to these medicines is reported 
worldwide and mass antibiotics administration during out-
breaks is not recommended. It does not impede the spread 
of cholera and enhances antimicrobial resistance [3, 4].  
The possible mistakes and errors in providing treatment 
to patients with cholera are using inadequate type of fluids 
to rehydrate them and underestimating the amount of fluids 
needed. 
The fatality rate is high in untreated patients and it can 
reach from 50% to 70%. Initiation of proper rehydration ther-
apy reduces the mortality among severe cases to less than 
0.5%. During pregnancy the risk is approximately 8% [12].
CURRENT EPIDEMIOLOGICAL  
SITUATION WORLDWIDE
Vibrio cholerae has been known since the 19th century 
and it continues to infect and kill large numbers of people 
in a very short time. Favourable conditions for spreading the 
pathogen include crowded settlements without sanitation 
infrastructure and running water, such as peri-urban slums 
or refugees’ camps. 
The last WHO report containing complete data was 
issued in 2015. Forty-two countries reported a total of 
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172,454 cases with 1034 deaths due to cholera infec-
tion. During Haiti outbreak in 2011, the number of cholera 
infections was 340,311 cases. The majority of cases and 
deaths attributable to cholera were noted in Sub-Saharan 
Africa (41.3 and 74.6%, respectively), primarily in the Dem-
ocratic Republic of Congo, Kenya, Tanzania, Mozambique, 
Somalia and Nigeria. Case fatality rate was 1.25% [13]. It 
is well known that the reported numbers of cholera cases 
are underestimated. Probably there are 3 million cases 
and approximately 100,000 deaths annually attributable to 
V. cholera infection [14]. 
Cholera continues to be a public health problem mostly 
for low and middle-income countries, particularly in Asia, 
Africa and the Caribbean [15]. Almost 1.8 billion people 
around the world live in conditions conducive to infection 
by water contaminated with faeces and 2.4 billion people 
exist without proper sanitation infrastructure [3]. Cholera 
health effects are exacerbated by poor health, pregnancy, 
comorbidities, malnutrition and infancy [16]. In endemic 
regions, the morbidity is highest in children below 5 years.
The current outbreak in Yemen began in October 2016, 
it peaked in December and continued then the epidemic 
erupted again in April 2017. It is currently the largest out-
break in the world, with 5000 new infections a day. It is 
called a man-made humanitarian disaster, as a result of an 
ongoing civil war and a collapsing health system. More than 
half of all health facilities in Yemen have been damaged, 
destroyed or do not possess enough funds to continue ac-
tivity. As of August 19th, 2017 the number of cholera cases 
stands at 527,000 with 1997 deaths [17].  
The toxic mix of conflicts, civil war, famine, deteriorat-
ing hygiene and sanitation conditions is far from solving 
the situation in Yemen. Blockades on Saudi-controlled air 
and seaports preclude humanitarian aid and import of 
medicines [16]. 
The International Coordinating Group on Vaccine Provi-
sion promised to send 1 million doses of cholera vaccine 
to Yemen, which is approximately half of the global supply. 
Currently, the vaccine provision is intermitted, instead of 
it the efforts are made to improve access to clean water 
across the country [16]. It seems, however, that only the 
end of the civil war could end this humanitarian catastrophe. 
sUMMArY
It has been estimated that there are 1.3 to 4.0 million 
cases of illness and 21,000 to 143,000 deaths worldwide 
due to cholera annually [1]. It is expected that the global cli-
mate change, including rapid and often unplanned urbanisa-
tion, could also increase the rates of cholera infections [15]. 
Most of those infected will have no or mild symptoms, 
and can be successfully treated with oral rehydration solu-
tion [3], which reduces the mortality of severe cholera from 
over 10% to less than 0.5% [18]. A major determinant of 
host susceptibility to cholera is immunity acquired through 
a previous infection or cholera vaccination. A single episode 
of cholera protects against the subsequent infection [19]. 
Among nutritional factors, retinol deficiency is associated 
with an increased risk of cholera, and breastfeeding has 
been consistently shown to be protective against cholera 
[20]. Other determinants of human susceptibility to chol-
era include genetic factors, and interactions with other 
microbes.
The opportunities for cholera to strike arise in the set-
tings where populations are displaced, where people are 
left vulnerable by malnutrition, drought and low educational 
status, and where sanitation and hygiene are poor [15, 21]. 
The areas of increased risk include, in particular, peri-urban 
slums, where the basic infrastructure is not available, as 
well as camps for internally displaced persons or refugees, 
where minimum requirements of clean water and sanitation 
have not been met [3], or where the existing infrastructure 
has been destroyed during an ongoing war. This has clearly 
been reaffirmed in the ongoing conflict in Yemen [16].
In spite of the fact that cholera is treated easily, it re-
mains a global threat to public health and an indicator of 
inequity and lack of social development [3], especially in 
Sub-Saharan Africa, the region with the lowest coverage of 
improved water and sanitation facilities and a plethora of 
health system challenges. A cholera epidemic creates an 
additional burden on health facilities and personnel already 
stressed by HIV/AIDS, malaria, tuberculosis, and other infec-
tious and non-infectious causes of morbidity and mortality 
(e.g. malnutrition) [22]. In many settings, access to basic 
health care is also hampered by war [23]. All these factors 
impair rapid access to treatment which is essential during 
a cholera outbreak. Oral rehydration should be available in 
communities, in addition to larger centres that can provide 
intravenous fluids and 24 h care. With early and proper 
treatment, the case fatality rate should remain below 1% [3].
Safe water, sanitation and hygiene are the primary 
measures for cholera prevention and control, as well as 
breastfeeding of young infants, which protects against 
cholera and other enteric infections in endemic settings. 
Since 2010, killed whole-cell oral cholera vaccines have 
been recommended by the WHO as an additional tool for 
endemic and epidemic cholera prevention and control and 
for reducing the severity of the disease [1]. However, they 
should only be used in conjunction with improvements in 
water and sanitation to control cholera outbreaks and for 
prevention in areas known to be high risk for cholera. Under 
no circumstances should they replace conventional control 
measures. According to the results of trials conducted in 
different settings, the conferred protection at 6 months is 
80% and at 5 years it is 65% [24]. In order to facilitate the 
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fight against endemic and epidemic cholera, WHO created 
the world’s first oral cholera vaccine stockpile in 2013, 
which continues to expand and more than 11 million doses 
of oral cholera vaccines have been shipped for use in mass 
vaccination campaigns with WHO support up to June 21st, 
2017 [3]. 
Currently there are three WHO pre-qualified oral cholera 
vaccines: Dukoral®, Shanchol® and Euvichol®. All three 
vaccines require two doses for full protection [25]. While Du-
koral® is mainly used for travellers, providing approximately 
65% protection against cholera for 2 years, Shanchol® and 
Euvichol® do not require a buffer solution for administration, 
which makes them easier to administer to large numbers 
of people in emergency contexts [3]. 
Although cases in resource-rich settings are generally 
imported from travel to endemic or epidemic settings, most 
travellers from resource-rich to resource-limited settings are 
at low risk for cholera. Select travellers, such as aid, refugee, 
and healthcare workers planning to work among displaced 
populations (e.g., those in crowded camps and urban slums) 
in endemic or epidemic settings, are at a higher risk and 
may benefit from pre-travel cholera vaccination. Travellers 
should follow general precautions such as avoidance of tap 
water, food from street vendors, raw or uncooked seafood, 
and raw vegetables. Water can be treated with chlorine or 
iodine, by filtration, or by boiling. The epidemiologic clues 
that might increase the suspicion of V. cholerae infection 
in a patient with watery diarrhoea include travel to endemic 
areas where cholera outbreaks are occurring or ingestion 
of undercooked or raw shellfish.
CONCLUSIONS 
Cholera, an easily treatable disease, still causes signif-
icant mortality and remains a global threat to public health 
as well as an indicator of inequity and lack of social equality. 
Moreover, politically, economically and religiously motivat-
ed armed conflicts which frequently are located in already 
underdeveloped areas, and which often cause internal dis-
placement of persons or flight of refugees and the destruc-
tion of water and sanitation infrastructure, force people to 
live in conditions where the only water available for drinking 
is that contaminated with human faeces. In 21st century, it 
should be considered shameful for the global community.
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